Benitec Reports Positive Phase 1b/2a Results For BB-301 In Oculopharyngeal Muscular Dystrophy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 13 2024
0mins
Should l Buy ?
Source: Business Insider
Clinical Trial Results: Benitec Biopharma Inc. reported positive outcomes in a Phase 1b/2a study of BB-301 for Oculopharyngeal Muscular Dystrophy, with two subjects showing significant improvements in swallowing after receiving the low-dose gene therapy.
Safety and Efficacy: The treatment was well-tolerated with no significant adverse events, and both subjects demonstrated clinically meaningful enhancements in their swallowing abilities over time, as measured by various scoring systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
